How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?

Authors

Arvind Suresh, Darren Pan, Jodi Lipof, Anupama Kumar, Shagun Arora, Peter Sayre, Jeffrey Wolf, Thomas Martin, Ajai Chari, Alfred Chung

Published in

Immunotherapy. Pages 1-14. Oct 17, 2025. Epub Oct 17, 2025.

Abstract

B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory multiple myeloma (RRMM), yet relapse is still common for most patients. A variety of different salvage treatment strategies have been studied in the last several years to address several resistance mechanisms that lead to relapse after BCMA CAR-T. To date, there are no clear guidelines regarding treatment sequencing strategies for salvage therapy. This review will investigate the current landscape of available salvage therapies and data supporting their use, as well as possible treatment sequencing strategies to maximize clinical outcomes in this difficult-to-treat population.

PMID:
41104991
Bibliographic data and abstract were imported from PubMed on 17 Oct 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.